| Year |
Citation |
Score |
| 2023 |
Martinez SR, Elix CC, Ochoa PT, Sanchez-Hernandez ES, Alkashgari HR, Ortiz-Hernandez GL, Zhang L, Casiano CA. Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance. International Journal of Molecular Sciences. 24. PMID 37108293 DOI: 10.3390/ijms24087130 |
0.717 |
|
| 2021 |
Ortiz-Hernandez GL, Sanchez-Hernandez ES, Ochoa PT, Elix CC, Alkashgari HR, McMullen JRW, Soto U, Martinez SR, Diaz Osterman CJ, Mahler M, Roy S, Casiano CA. The LEDGF/p75 Integrase Binding Domain Interactome Contributes to the Survival, Clonogenicity, and Tumorsphere Formation of Docetaxel-Resistant Prostate Cancer Cells. Cells. 10. PMID 34685704 DOI: 10.3390/cells10102723 |
0.758 |
|
| 2021 |
Almahmoud S, Elix CC, Jones JO, Hopkins CR, Vennerstrom JL, Zhong HA. Virtual screening and biological evaluation of PPARγ antagonists as potential anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 46: 116368. PMID 34433102 DOI: 10.1016/j.bmc.2021.116368 |
0.387 |
|
| 2019 |
Elix CC, Salgia MM, Otto-Duessel M, Copeland BT, Yoo C, Lee M, Tew BY, Ann D, Pal SK, Jones JO. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. The Prostate. PMID 31769890 DOI: 10.1002/Pros.23928 |
0.396 |
|
| 2019 |
Salgia MM, Elix CC, Pal SK, Jones JO. Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer. American Journal of Clinical and Experimental Urology. 7: 98-109. PMID 31317050 |
0.488 |
|
| 2017 |
Elix C, Pal SK, Jones JO. The role of peroxisome proliferator-activated receptor gamma in prostate cancer. Asian Journal of Andrology. PMID 28597850 DOI: 10.4103/Aja.Aja_15_17 |
0.491 |
|
| 2017 |
Ríos-Colón L, Cajigas-Du Ross CK, Basu A, Elix C, Alicea-Polanco I, Sanchez TW, Radhakrishnan V, Chen CS, Casiano CA. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget. PMID 28212536 DOI: 10.18632/Oncotarget.15323 |
0.827 |
|
| 2017 |
Tew BY, Hong TB, Otto-Duessel M, Elix C, Castro E, He M, Wu X, Pal SK, Kalkum M, Jones JO. Vitamin K epoxide reductase regulation of androgen receptor activity. Oncotarget. PMID 28099154 DOI: 10.18632/Oncotarget.14639 |
0.559 |
|
| 2016 |
Rios-Colon L, Sanchez TW, Elix CC, Alicea I, Basu A, Ross CD, Neamati N, Casiano CA. Abstract B06: Repositioning HIV-based small molecule inhibitors of the stress oncoprotein LEDGF/p75 to overcome prostate cancer resistance to taxane chemotherapy Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-B06 |
0.828 |
|
| 2015 |
Colon LR, Elix C, Alicea I, Basu A, Ross CD, Sanchez T, Neamati N, Casiano C. Abstract 5411: Repositioning HIV-based small molecule inhibitors of the stress survival oncoprotein LEDGF/p75 to overcome taxane resistance in prostate cancer Cancer Research. 75: 5411-5411. DOI: 10.1158/1538-7445.Am2015-5411 |
0.865 |
|
| 2014 |
Colon LR, Elix C, Basu A, Sanchez TW, Neamati N, Casiano CA. Abstract 775: Targeting the stress survival oncoprotein LEDGF/p75 to overcome prostate cancer resistance to taxane therapy Cancer Research. 74: 775-775. DOI: 10.1158/1538-7445.Am2014-775 |
0.873 |
|
| 2013 |
Rios-Colon L, Basu A, Elix C, Casiano CA, León MD. Abstract 892: The stress oncoprotein LEDGF/P75 promotes selective resistance to multiple chemotherapeutic drugs in prostate cencer cells. Cancer Research. 73: 892-892. DOI: 10.1158/1538-7445.Am2013-892 |
0.824 |
|
| 2012 |
Basu A, Ríos-Colón L, Nishikawa C, Elix C, Nguyen L, Djeu J, León MD, Casiano C. Abstract 775: Targeting the transcriptional coactivator LEDGF/p75 to overcome chemoresistance in prostate cancer Cancer Research. 72: 775-775. DOI: 10.1158/1538-7445.Am2012-775 |
0.846 |
|
| 2012 |
Ríos-Colón L, Basu A, Cajigas C, Elix C, Casiano CA. Abstract B76: Circumventing chemoresistance as a strategy to reduce the mortality disparities associated with advanced prostate cancer. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B76 |
0.846 |
|
| Show low-probability matches. |